The antifibrotic function of Foxm1 has been reported in cardiac hypertrophy and fibrosis, diabetes, and pulmonary fibrosis (Penke et al., 2018; Yang et al., 2016). This evidence concerns the gene FOXM1 and cardiac hypertrophy.